Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Drug combo outsmart advanced liver cancer?

NCT ID NCT06487559

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether combining two investigational drugs, livmoniplimab and budigalimab, can safely help people with advanced liver cancer (hepatocellular carcinoma) that has worsened after initial treatment. The study involves about 20 adults in China with a specific type of liver cancer (Child-Pugh A) who have already received an immune checkpoint inhibitor. Participants receive the drugs by intravenous infusion every three weeks, and researchers will monitor side effects, how the drugs move through the body, and any signs of tumor response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Livmoniplimab (ABBV-151) combined with budigalimab (ABBV-181), both given as intravenous infusions
What this could lead to
If successful, this combination could offer a new treatment option for advanced liver cancer patients who have not responded to standard first-line therapy.
What could go wrong
This is an early-phase study with a small number of participants, so results may not apply broadly. The drugs may cause side effects or fail to show meaningful benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

3 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Locally advanced or metastatic and/or unresectable HCC * Child-Pugh A * Barcelona Clinic Liver Cancer stage B or C * Eastern Cooperative Oncology Group (ECOG) Perfromance Status of 0-1 * Received an immune checkpoint inhibitor in 1L HCC treatment regimen * Adequate hematologic and end-organ function Exclusion Criteria: * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases as outlined in the protocol. * History of malignancy other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \> 90%). * History of autoimmune, immune deficiency, or inflammatory disorders including, but not limited to, inflammatory bowel disease, systemic lupus erythematosus, sarcoidosis, Wegener syndrome, rheumatoid arthritis, antiphospholipid antibody syndrome, Guillain-Barre syndrome, or multiple sclerosis * History of clinically significant conditions such as but not limited to the following: renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months that in Investigator's opinion, would adversely affect the subject's participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma (HCC)

Contacts and locations

Locations

  • Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928

    Beijing, Beijing Municipality, 100069, China

  • Harbin Medical University Cancer Hospital /Id# 262070

    Harbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital /ID# 262098

    Zhengzhou, Henan, 450008, China

  • Hubei Cancer Hospital /ID# 262030

    Wuhan, Hubei, 430079, China

  • Liaoning Cancer Hospital & Institute /ID# 268023

    Shenyang, Liaoning, 110042, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443

    Fuzhou, Fujian, 350012, China

  • Nanfang Hospital of Southern Medical University /ID# 262091

    Guangzhou, Guangdong, 510515, China

  • Sun Yat-Sen University Cancer Center /ID# 262092

    Guangzhou, Guangdong, 510060, China

  • The Second Affiliated Hospital of Nanchang University /ID# 262085

    Nanchang, Jiangxi, 330008, China

  • Zhejiang Cancer hospital /ID# 262046

    Hangzhou, Zhejiang, 310022, China

  • Zhongshan Hospital Fudan University /ID# 262135

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.